BR112023019309A2 - Tratamento de hidradenite supurativa com orismilaste - Google Patents

Tratamento de hidradenite supurativa com orismilaste

Info

Publication number
BR112023019309A2
BR112023019309A2 BR112023019309A BR112023019309A BR112023019309A2 BR 112023019309 A2 BR112023019309 A2 BR 112023019309A2 BR 112023019309 A BR112023019309 A BR 112023019309A BR 112023019309 A BR112023019309 A BR 112023019309A BR 112023019309 A2 BR112023019309 A2 BR 112023019309A2
Authority
BR
Brazil
Prior art keywords
treatment
hidradenitis suppurativa
orismilaste
suppurativa
hidradenitis
Prior art date
Application number
BR112023019309A
Other languages
English (en)
Inventor
Anne Weiss
Hjardem Taudorf Elisabeth
B E Jemec Gregor
Kim Kjøller
Morten Sommer
Philippe Andres
Original Assignee
Union Therapeutics As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2103975.5A external-priority patent/GB202103975D0/en
Application filed by Union Therapeutics As filed Critical Union Therapeutics As
Publication of BR112023019309A2 publication Critical patent/BR112023019309A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Medicinal Preparation (AREA)

Abstract

tratamento de hidradenite supurativa com orismilaste. um composto de fórmula ou um sal, solvato ou hidrato farmaceuticamente aceitável do mesmo, para uso no tratamento de hidradenite supurativa (hs) em um indivíduo.
BR112023019309A 2021-03-22 2022-03-22 Tratamento de hidradenite supurativa com orismilaste BR112023019309A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2103975.5A GB202103975D0 (en) 2021-03-22 2021-03-22 Treatment of HS
GB202118420 2021-12-17
GB202201381 2022-02-03
PCT/EP2022/057472 WO2022200339A1 (en) 2021-03-22 2022-03-22 Treatment of hidradenitis suppurativa with orismilast

Publications (1)

Publication Number Publication Date
BR112023019309A2 true BR112023019309A2 (pt) 2023-10-31

Family

ID=81346285

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023019309A BR112023019309A2 (pt) 2021-03-22 2022-03-22 Tratamento de hidradenite supurativa com orismilaste

Country Status (8)

Country Link
EP (1) EP4313043A1 (pt)
JP (1) JP2024511141A (pt)
KR (1) KR20230159485A (pt)
AU (1) AU2022245186A1 (pt)
BR (1) BR112023019309A2 (pt)
CA (1) CA3212316A1 (pt)
IL (1) IL306020A (pt)
WO (1) WO2022200339A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202205715D0 (en) * 2022-04-19 2022-06-01 Union Therapeutics As Treatment of neutrophilic dermatoses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2585469B1 (en) 2010-06-24 2016-05-25 Leo Pharma A/S Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors
JP6785666B2 (ja) 2014-06-23 2020-11-18 レオ ファーマ アクティーゼルスカブ １，３−ベンゾジオキソール複素環化合物の調製方法
ES2961237T3 (es) 2015-12-18 2024-03-11 Union Therapeutics As Métodos para la preparación de compuestos heterocíclicos de 1,3-benzodioxol
CA3064033A1 (en) 2017-06-20 2018-12-27 Leo Pharma A/S Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
EP3911304B1 (en) 2019-01-15 2023-09-06 UNION therapeutics A/S Modified release tablet formulations containing phosphodiesterase inhibitors

Also Published As

Publication number Publication date
WO2022200339A1 (en) 2022-09-29
EP4313043A1 (en) 2024-02-07
AU2022245186A1 (en) 2023-10-05
IL306020A (en) 2023-11-01
CA3212316A1 (en) 2022-09-29
KR20230159485A (ko) 2023-11-21
JP2024511141A (ja) 2024-03-12

Similar Documents

Publication Publication Date Title
CO2021009078A2 (es) Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1)
BR112018073504A2 (pt) processo para preparar (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazol[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida e sais da mesma
BRPI0711646C1 (pt) solução aquosa estéril de um sal de ácido succínico
BR112015024530A2 (pt) composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto
BR112022002532A2 (pt) Compostos heterocíclicos como inibidores de quinase
BR112018069515A2 (pt) uso de masitinibe para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica
BR112012021905A2 (pt) tratamento de nefrite lúpica usando laquinimod
BRPI0613570A8 (pt) composto ou um sal do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar doenças mediadas por glk, e, processo para a preparação de um composto.
BR112022015161A2 (pt) Terapia de combinação para tratamento de crescimento celular anormal
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
BR112012031580A2 (pt) derivado de tetra-hidrocarbolina
BR112021020681A2 (pt) Agonista de molécula pequena de fxr e método de preparação para o mesmo e uso do mesmo
BR112023019309A2 (pt) Tratamento de hidradenite supurativa com orismilaste
CL2013003307A1 (es) Agente que comprende ciazofamida o fenamidona; y su uso para tratar micosis en peces e invertebrados en todos sus estadios de desarrollo causada por hongos de los generos saprolegnia, achlya y aphanomyces (div.sol.n°1056-08).
BR112022000251A2 (pt) Derivados macrocíclicos de espirociclo como inibidores de mcl-1
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
BR112019023453A2 (pt) Compostos de formimidamidina úteis contra microorganismos fitopatogênicos
CR20200522A (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
CL2020001482A1 (es) Composición y método para tratar el linfoma periférico de linfocitos t y el linfoma cutáneo de linfocitos t.
BR112018073553A2 (pt) medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.
BR112023000770A2 (pt) Inibidor de egfr
BR112015032961A2 (pt) formulação química, e, métodos para tratar resíduos humanos ou animais, para eliminar ou reduzir crescimento microbiano em um local de tratamento e para tratar um animal com uma doença ou distúrbio associado a uma infecção microbiana
BR112018073556A2 (pt) medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato .
BR112021018858A2 (pt) Chiauranibe para tratamento de câncer de pulmão de células pequenas
MX2020011991A (es) Inhibidores de la oncoproteina ras, metodos de produccion y metodos de uso de los mismos.